- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 17, 2025
Product Development
Lundbeck’s next chapter: from psychiatry to rare neuro
Leaving past limitations behind, Danish pharma widens its technology aperture to brain shuttles, AI and more
BioCentury | Jul 20, 2023
Data Byte
The PCOS pipeline: tiny but diverse
Less than 10 companies taking a shot at PCOS. With each testing a different MoA, they promise broad learnings
BioCentury | Nov 19, 2021
Data Byte
New mechanisms enter the Cushing disease pipeline
The fourth disease-modifying therapy is nearing the market
BioCentury | Feb 20, 2020
Finance
With $88M series B, Spruce seeks short path to approval in rare endocrine disorder
Four-year-old Spruce chose an investor syndicate with experience in rare diseases and public markets
BioCentury | Mar 16, 2017
Targets & Mechanisms
Bone appétit!
How a bone hormone could help treat obesity
Items per page:
1 - 10 of 30